Rigel Pharmaceuticals | RIGL - Kısa Vadeli Yükümlülükler





Kısa Vadeli Yükümlülükler Değişiklik Tarih
Agenus USD 231.82M 17.42M 2026-06
Amgen USD 23.23B 2.27B 2026-09
Anika Therapeutics USD 22.15M 1.18M 2026-06
Arrowhead Research USD 283.35M 11.87M 2026-06
AstraZeneca USD 31.27B 286M 2026-09
BioMarin Pharmaceutical USD 1.6B 59.17M 2026-09
Bristol-Myers Squibb USD 18.75B 94M 2026-09
Celldex Therapeutics USD 60.52M 808K 2026-09
Daiichi Sankyo JPY 882.78B 117.08B 2026-09
Eli Lilly USD 47B 745M 2026-09
Halozyme Therapeutics USD 476.09M 131.65M 2026-09
Heron Therapeutics USD 92.14M 1.63M 2026-06
Intrexon USD 23.02M 38K 2024-06
Ionis Pharmaceuticals USD 315.64M 401.36M 2026-06
Karyopharm Therapeutics USD 117.3M 25.24M 2026-03
Ligand Pharmaceuticals USD 500.57M 453.83M 2026-09
MacroGenics USD 108.82M 12.88M 2026-06
Neurocrine Biosciences USD 984.6M 110.1M 2026-09
Pfizer USD 31.73B 920M 2026-09
Regeneron Pharmaceuticals USD 6.2B 671.5M 2026-09
Rigel Pharmaceuticals USD 94.4M 7.76M 2025-09
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Ultragenyx Pharmaceutical USD 389M 38M 2026-09
Veracyte USD 84.21M 21.47M 2026-09